Shopping Cart 0
Cart Subtotal
USD 0

KOL Perspectives: Rituximab Use in Lupus

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 5000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 7500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

KOL Perspectives: Rituximab Use in Lupus

Summary

This KOL Insight briefing focuses on KOLs views of Rituximab Use in Lupus.

Questions topics-

- Current & future use of RTX in lupus

- Views on RTX's Phase II/III EXPLORER trial re-analysis

- Opinion on data demonstrating that RTX is effective for the management of refractory SLE

- Views on data from the Phase II SYNBIoSe study assessing RTX + BEL combination therapy

- Lupus patients most suitable for RTX + BEL combination therapy

- Use of RTX + BEL combination therapy

Key Highlights

- Most US KOLs stated that future launch of biosimilar RTX will have no impact on their overall use of RTX, but uptake will depend on price

- Most KOLs highlighted that the level of background medication used in the EXPLORER trial was too high and consequently impeded results

- Most KOLs flagged that payers may be a barrier to combination therapy use, especially given the lack of approval for RTX in lupus.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our Lupus key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs-

- 5 Europe-based & 5 N. America-based

- Interviews performed during Q2 2018

KOL data is analyzed to produce-

- Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on Rituximab Use in Lupus

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Table Of Content

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Rituximab, lupus, biosimilar, combination therapy


Companies

Roche

GSK

KOL Perspectives: Rituximab Use in Lupus

Summary

This KOL Insight briefing focuses on KOLs views of Rituximab Use in Lupus.

Questions topics-

- Current & future use of RTX in lupus

- Views on RTX's Phase II/III EXPLORER trial re-analysis

- Opinion on data demonstrating that RTX is effective for the management of refractory SLE

- Views on data from the Phase II SYNBIoSe study assessing RTX + BEL combination therapy

- Lupus patients most suitable for RTX + BEL combination therapy

- Use of RTX + BEL combination therapy

Key Highlights

- Most US KOLs stated that future launch of biosimilar RTX will have no impact on their overall use of RTX, but uptake will depend on price

- Most KOLs highlighted that the level of background medication used in the EXPLORER trial was too high and consequently impeded results

- Most KOLs flagged that payers may be a barrier to combination therapy use, especially given the lack of approval for RTX in lupus.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our Lupus key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs-

- 5 Europe-based & 5 N. America-based

- Interviews performed during Q2 2018

KOL data is analyzed to produce-

- Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on Rituximab Use in Lupus

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Rituximab, lupus, biosimilar, combination therapy


Companies

Roche

GSK